Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel, Miami Beach, FL. Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson websit.

Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference

Coca-Cola

McDonald's

Procter & Gamble

Sempra Energy

Target

Exxon Mobil

Easily one of the top talking points of last year is that with the economy avoiding a recession, mitigation protocols – such as targeting stable dividend stocks – seem rather unnecessary. Nevertheless, it doesn't hurt to hope for the best but to be prepared for the worst.

7 Stable Dividend Stocks to Ease Lingering Market Jitters

Disney

Visa

The Dow Jones Industrial Average has been Wall Street's health barometer since the late 1800s. The Dow comprises 30 time-tested, multinational businesses, which means it's a great place for investors to search for amazing deals.

3 Dow Stocks You Can Confidently Buy Now and Hold Forever

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12th, at the Fontainebleau Miami Beach, FL. Joe Wolk, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio.

Johnson & Johnson to Participate in the Leerink Global Biopharma Conference

Bristol-Myers

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Eli Lilly

Merck

Pfizer

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Caterpillar

Enterprise Products Partners

NextEra Energy

If you can identify the right passive income blue-chip stocks, you will be able to enjoy steady income each quarter, and some companies have been rewarding investors for decades. Wouldn't it be nice to enjoy passive income frequently while your original investment continues to grow?

Passive Income Powerhouses: 7 Blue-Chip Stocks to Own Now

Ambrx Biopharma Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

Johnson & Johnson focuses on pharmaceuticals and medical devices after spinning off its consumer-health segment. The company's solid pipeline of cancer, immunology, and neurology drugs, along with its leading medical device portfolio, offer growth prospects. Johnson & Johnson reported strong Q4 earnings, beating revenue forecasts, and expects continued growth in pharmaceutical sales and revenue in FY24.

Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds

Lowe's

T. Rowe Price Group

Income-oriented investors often look to  dividend stocks to generate a reliable cash flow stream. However, not all dividend payers are created equal.

Dividend Dynasties: 3 Stocks Set to Deliver Consistent Income

Starbucks

If you are here to build a portfolio that thrives in all seasons, consider dividend stocks. They can generate steady returns and provide stability to your investments.

3 Dividend Stocks to Cling to This Year

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.

J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen

Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.

Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For

The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.

Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing

Shares of Johnson & Johnson offer a 3% dividend yield and the confidence that comes with 61 consecutive years of annual dividend raises. Last year, Johnson & Johnson spun off its consumer health division into a new company called Kenvue.

Is Johnson & Johnson a Good Dividend Stock to Buy Now?

AbbVie

Archer-Daniels-Midland Company

Amcor Plc

Air Products and Chemicals

Franklin Resources

Chevron

Essex Property Trust

Fastenal

Federal Realty Investment Trust

Hormel Foods

Kimberly-Clark

Kenvue

Realty Income Corp

V.F.

Walgreens

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com. 67 Aristocrats, screened as of February 5, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 11.95%-40.69% topped-by APD & ADM.

5 Dividend Aristocrats Signal Buy In February And 6 To Watch

Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say.

Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar

Johnson & Johnson has a massive footprint in healthcare, even after spinning off its consumer products segment. Fantastic financials give the company lots of flexibility to acquire growing assets strategically.

Is Johnson & Johnson Stock a Buy Now?

GlaxoSmithKline

Intuitive Surgical

Medtronic

Teladoc

Vertex Pharmaceuticals

Healthcare stocks in 2024 are charting an impressive course, emerging as formidable contenders in the investment sphere. After weathering a challenging 2023, these stocks are on the rise, with the S&P 500 Health Care index showcasing an almost 11% rise in the last three months alone.

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024

News for Johnson & Johnson Stock (JNJ)